SCHEMBL6841899

SCHEMBL6841899

O=C(NCCc1ccccc1)c1ccc(C(=O)c2ccc(C(=O)NCCc3ccccc3)cc2)cc1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 1/20 0.78
HDAC8 Q9BY41 1/20 0.78
HDAC6 Q9UBN7 1/20 0.78
RAB9A P51151 11/20 0.76
NPC1 O15118 10/20 0.76
SMN1; SMN2 Q16637 4/20 0.70
MLYCD O95822 2/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
TAAR1 Q96RJ0 1/20 0.68
MAPT P10636 2/20 0.66
HSD17B10 Q99714 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
KDM1A O60341 1/20 0.62
NFKB1 P19838 1/20 0.62
NFKB2 Q00653 1/20 0.62
RELA Q04206 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751214 0.91 HDAC2 (0.80) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL7282271 0.89 HDAC2 (0.78) HDAC2HDAC8HDAC6RAB9ANPC1
Hydrochloric Acid SCHEMBL28193721 0.89 HDAC2 (0.77) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL14302481 0.89 MEN1 (0.69) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL2919151 0.88 HDAC2 (0.76) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL6571020 0.88 HDAC2 (1.00) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL13073425 0.88 HDAC2 (0.76) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL16900376 0.86 RAB9A (1.00) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL7702108 0.86 RAB9A (1.00) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL95051 0.86 HDAC2 (0.73) HDAC2HDAC8HDAC6RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2004-04-01 US disclosed
EP-1360167-A1 SYMMETRICALLY DISUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING POLY (ADP-RIBOSE) GLYCOHYDROLASE, AND METHODS FOR THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-6635786-B2 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2003-10-21 US disclosed
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2002-09-19 US disclosed
WO-2002057211-A1 SYMMETRICALLY DISUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING POLY (ADP-RIBOSE) GLYCOHYDROLASE, AND METHODS FOR THEIR USE GUILFORD PHARMACEUTICALS, INC. (US) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 HDAC2 712/4885HDAC8 895/4885HDAC6 499/4885
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 HDAC2 712/4885HDAC8 895/4885HDAC6 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.